Bristol Myers Squibb Co 8-K, filed Mar 17, 2022
Bristol Myers Squibb Co (BMY)
8-K
2022-03-17
For: 2022-03-14
View Original
Added on
April 02, 2026
About this 8-K
Bristol Myers Squibb Co filed this 8-K on March 17, 2022, reporting on events of March 14, 2022.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 14, 2022
(Exact name of registrant as specified in its charter)
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission File Number)
|
(I.R.S Employer
Identification No.)
|
(Address of principal executive offices) (zip code)
Registrant’s telephone number, including area code: (212 )
546-4200
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
||
|
|
||
|
|
||
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to
use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02 |
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
|
Effective April 25, 2022, Ms. Sharon Greenlees will be appointed Senior Vice President and Controller of Bristol-Myers Squibb
Company (the “Company”). Ms. Karen Murphy Santiago, Senior Vice President and Controller, will leave the Company by May 1, 2022. Ms. Greenlees, 50, most recently, from July 2021, served as Vice President and Controller, R&D Finance and Operations at AbbVie Inc. and prior to that, she served in multiple roles of increasing
responsibility, including Head of Supply Chain Finance from 2020 to 2021, Head of Pricing, U.S. Commercial from 2018 to 2020, Vice President of Investor Relations from 2016 to 2018 and Vice President and Assistant Corporate Controller from 2012
to 2016. Ms. Greenless has a B.S. in Accounting and is a Certified Public Accountant.
Ms. Greenlees is not a party to any arrangement or understanding regarding her selection as an officer. There are no family relationships between Ms.
Greenlees and any director or executive officer of the Company. Ms. Greenlees is not a party to any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
|
BRISTOL-MYERS SQUIBB COMPANY
|
|||
|
Dated: March 17, 2022
|
By:
|
/s/ Kimberly M. Jablonski
|
|
|
Name:
|
Kimberly M. Jablonski
|
||
|
Title:
|
Corporate Secretary
|
||